

Provider Bulletin

Central Health Medicare Plan

June 13, 2025

☒ Alameda ☒ Contra Costa ☒ Fresno ☒ Imperial ☒ Kern ☒ Kings ☒ Los Angeles ☒ Madera ☒ Orange
☒ Placer ☒ Riverside ☒ Sacramento ☒ San Bernardino ☒ San Diego ☒ San Francisco ☒ San Joaquin
☒ San Mateo ☒ Santa Clara ☒ Solano ☒ Stanislaus ☒ Tulare ☒ Ventura ☒ Yolo

2025 Annual Clinical Hierarchy

This is an advisory notification to Central Health Medicare Plan (CHP) network providers applicable to CHP Medicare business.

What you need to know:

MHC medical necessity criteria are based on the most current available clinical evidence supporting safety and efficacy. The following are considered approved and acceptable resources for clinical criteria. The order in which they are listed is regarded as the acceptable hierarchy for use.

MHC's Delegation Oversight shall incorporate these standards as a part of Utilization Management (UM) oversight activities.

1. Medicare Hierarchy

When benefits are covered by Medicare, clinicians follow the hierarchy of decision making:

- i. Applicable Federal mandates/regulations and National Coverage Determinations (NCDs).
- ii. General coverage guidelines included in original Medicare manuals (e.g., Medicare Benefit Policy Manual, etc.) and instructions (e.g., CMS transmittals, MLN articles, HPMS memos, etc.) unless superseded by regulation or related instructions.
- iii. Local Coverage Determinations (LCDs) as published by the applicable Medicare Administrative Contractor (MAC) for the jurisdiction where services are being rendered and any applicable Local Coverage Articles.
- iv. Licensed external decision-making criteria, including MCG as applicable.
- v. Corporate guidance documents and policies, including Molina Clinical Policy (MCP) or if applicable, Delegated 3rd party clinical criteria guidelines

Continued page 2

Provider Action

Please review and familiarize yourself with the 2025 Medicare Clinical Hierarchy and criteria expectations. No further action is required.

What if you need assistance?

If you have any questions regarding the notification, please contact your CHP Provider Relations Representative at PRCalifornia@molinahealthcare.com.



- vi. The following specialty clinical decision aids, where applicable:
 - American Society of Addiction Medicine (ASAM) Criteria
 - National Comprehensive Cancer Network (NCCN) guidelines
 - National Comprehensive Cancer Network (NCCN) guidelines
 - Level of Evidence 2A or above is considered recommended.
- v. Hayes Technology Assessments
 - Hayes Rating of B or better for the treatment/technology may be considered for approval.
 - Hayes Rating of C or below for the treatment/technology demonstrates unproven benefit. Some published evidence suggests that safety and impact on health outcomes are at least comparable to standard treatment/testing. However, substantial uncertainty remains about safety and/or impact on health outcomes because of poor-quality studies, sparse data, conflicting study results, and/or other concerns.
- viii. All internal coverage criteria utilized by Molina and its delegated entities must be reviewed and approved for UM use by the Medicare Advantage UM committee.

When decision support criteria are not available, delegated entities may do one of the following:

1. Adhere to the existing process for ad hoc review of current literature for urgent needs.
2. Request two (2) independent scientific or medical documents with relevant clinical evidence supporting the assertion that the requested treatment would benefit the patient and be a clinical advantage over its competitors from the provider.
 - Reliable evidence may be obtained from good-quality randomized controlled trials or minimally biased prospective cohort/comparison studies.
 - Case reports, retrospective studies, and abstracts are not sufficient.
 - A technology considered an established standard of medical practice that has published data with evidence supporting its effectiveness may be considered (e.g., transplantation with donor bank data supporting increased life expectancy).
3. When published evidence is not available on topics that are considered standard of care, the Delegated Entity's evidence-based policies may be used for UM determinations.
4. Delegates shall consider the individual healthcare needs of each member when applying the criteria for coverage and prior to making coverage decisions. These factors shall include, at minimum, but may not be limited to:
 - Age
 - Comorbidities
 - Complications
 - Progress of treatment
 - Psychosocial situations
 - Home environment, when applicable
 - Local hospitals' ability to provide all recommended services within the estimated length of stay
 - Availability of any local delivery systems in the organization's service area as needed to support the patient after hospital discharge (e.g., skilled nursing facilities, Sub-acute care facilities, & home care agencies).
 - Coverage of benefits for Subacute or skilled nursing facilities, home care, or other local delivery systems as needed.

Delegates shall use clinical information to make UM determinations that include but may not be limited to:

1. Office and hospital records history of the presenting problem.
2. History of the presenting problem.
3. Clinical exam.
4. Diagnostic testing results.
5. Treatment plan and progress notes.
6. Patient psychosocial history.
7. Information and consultations with the treating practitioner.
8. Evaluations from other health care practitioners and providers.
9. Photographs.
10. Operative and pathological reports.
11. Rehabilitation evaluations.
12. A printed copy of the criteria related to the request.
13. Information regarding benefits for services or procedures.
14. Information regarding the local delivery system.
15. Patient characteristics and information.
16. Information from responsible family members.